A Blood Filter Startup Lured Cancer Patients to the Caribbean. Two Died. Executives Hid It From the FDA.

ExThera Medical, a California startup, charged cancer patients $45,000 per session to filter their blood at a clinic in Antigua. The device was only FDA-approved for Covid-19 ICU patients. Two people died within a day of each other. The company's chief regulatory officer hid their deaths from federal regulators.

Those are the facts that emerged this week when the Department of Justice announced criminal charges against Dr. Sanja Ilic, ExThera's former chief regulatory officer, and a deferred prosecution agreement with the company itself.

The Setup

Here's how it worked. ExThera manufactured a blood filtration device called the Seraph 100. It uses heparin-coated microbeads to bind pathogens — viruses, bacteria, fungi — and pull them out of your bloodstream. The FDA gave it emergency use authorization in April 2020, specifically for adult Covid-19 patients in intensive care with confirmed or imminent respiratory failure.

That's what it was approved for. Covid. ICU. Respiratory failure.

What happened next is a case study in how desperation gets monetized.

An American billionaire named Alan Quasha saw potential in the device beyond Covid. His family's private equity firm, Quadrant Management, invested in ExThera and built an operation in Antigua. They purchased $10 million worth of filtering devices. They hired a local health clinic to administer treatments. Then they started marketing the device to people with late-stage cancer.

About two dozen patients made the trip to the Caribbean. They paid $45,000 each.

What the Company Already Knew

This wasn't a case of unforeseen complications. According to court documents, Dr. Ilic notified ExThera's leadership and regulatory staff about potential adverse events before treatments at the Antigua clinic began. She flagged "life-threatening" complications that patients could experience from using the device.

The treatments went ahead anyway.

In March and April 2024, Ilic learned that patients were declining. David Hudlow, 55, from Panama City, Florida. Kyle Chupp, 39, from Orillia, Ontario. Both died within a day of each other in April 2024, shortly after returning home from Antigua.

Under federal law, medical device manufacturers must report adverse events — including deaths — to the FDA. It's not optional. It's how the system catches dangerous products.

Ilic didn't report them. According to prosecutors, she understood that disclosing the deaths could trigger FDA scrutiny, cause clinical trial partners to withdraw, and jeopardize the company's financial prospects. At the time, ExThera had just secured $10 million and stood to receive millions more from distribution agreements. Ilic was also overseeing ExThera's first US clinical study testing the device on cancer patients.

Money won. Transparency lost.

The Penalty

Ilic agreed to plead guilty and faces up to three years in prison. ExThera entered a deferred prosecution agreement requiring $750,000 in criminal penalties — earmarked for victims' families — plus forfeiture of $5.7 million. The company must implement compliance and ethics programs and cooperate with ongoing investigations.

Neither Alan Quasha nor John Preston, an ExThera board member close to Quasha who helped promote the device to cancer patients, has been charged. Both deny wrongdoing. The investigation is ongoing.

ExThera, which once employed about 50 people, is now close to filing for Chapter 11 bankruptcy.

The Bigger Problem

This story is easy to read as one bad company doing one bad thing. It's more than that.

The CDC specifically warns that "oncology tourists are a vulnerable patient population because the fear caused by a cancer diagnosis can lead them to try potentially risky treatments." An estimated 150,000 to 320,000 Americans travel abroad for healthcare every year. Some go for legitimate procedures available elsewhere. Others go for treatments that can't legally be sold in the US — and can't legally be sold for a reason.

The pipeline works like this: a real medical device gets limited FDA approval for a narrow use. Investors see broader potential. They set up operations in jurisdictions with lighter regulation. They market to the people most willing to try anything — late-stage cancer patients who've run out of conventional options.

The Caribbean is a common destination. So is Mexico. So are parts of Central America. The pattern repeats across stem cell clinics, experimental gene therapies, and now blood filtration.

What makes ExThera's case unusual isn't the offshore treatment or the unapproved use. It's that prosecutors could prove the company knew about the risks, knew about the deaths, and chose to hide them. Most cases don't generate a paper trail that clean.

What Gets Lost

David Hudlow was 55. Kyle Chupp was 39. They were people who ran out of options and went looking for one more. That's not irrational. When your doctor tells you there's nothing left to try, you search. You find companies offering hope. You fly to the Caribbean. You pay $45,000.

The system that's supposed to catch dangerous treatments before they reach desperate patients has gaps wide enough to fly through — literally. FDA approval for one condition doesn't prevent offshore marketing for another. Adverse event reporting depends on the people who have the most to lose from reporting.

ExThera's blood filter might someday prove useful for cancer treatment. The company had started a legitimate Phase I clinical trial. That's the right path — slow, careful, transparent. What happened in Antigua was the opposite. Fast, secretive, and built on the bet that nobody would notice two deaths in a Caribbean clinic.

Somebody noticed.